lorviqua
pfizer europe ma eeig - lorlatinib - krabbamein, lungnakrabbamein - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
lydisilka
estetra sprl - estetrol monohydrate, drospirenone - contraceptives, oral - hormón kynlíf og stillum kynfæri - getnaðarvörn til inntöku. the decision to prescribe lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (vte), and how the risk of vte with lydisilka compares with other combined hormonal contraceptives (chcs) (see sections 4. 3 and 4.
crestor filmuhúðuð tafla 5 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 5 mg
crestor filmuhúðuð tafla 40 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg
crestor filmuhúðuð tafla 20 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
crestor filmuhúðuð tafla 10 mg
astrazeneca a/s - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg
rosuvastatin actavis filmuhúðuð tafla 20 mg
actavis group ptc ehf. - rosuvastatinum kalsíum - filmuhúðuð tafla - 20 mg
rosuvastatin actavis filmuhúðuð tafla 10 mg
actavis group ptc ehf. - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg
rosuvastatin krka filmuhúðuð tafla 40 mg
krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 40 mg
rosuvastatin krka filmuhúðuð tafla 10 mg
krka sverige ab - rosuvastatinum kalsíum - filmuhúðuð tafla - 10 mg